Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals

被引:37
作者
Smit, Cornelis [1 ,2 ]
Wasmann, Roeland E. [3 ]
Goulooze, Sebastiaan C. [2 ]
Wiezer, Marinus J. [4 ]
van Dongen, Eric P. A. [5 ]
Mouton, Johan W. [6 ]
Bruggemann, Roger J. M. [3 ]
Knibbe, Catherijne A. J. [1 ,2 ]
机构
[1] St Antonius Hosp, Dept Clin Pharm, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands
[2] Leiden Univ, Leiden Acad Ctr Drug Res, Dept Syst Biomed & Pharmacol, Leiden, Netherlands
[3] Radboudumc, Radboud Inst Hlth Sci, Dept Pharm, Nijmegen, Netherlands
[4] St Antonius Hosp, Dept Surg, Nieuwegein, Netherlands
[5] St Antonius Hosp, Dept Anesthesiol, Nieuwegein, Netherlands
[6] Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands
关键词
glycopeptides; morbid obesity; obesity; pharmacokinetics; pharmacology; vancomycin; OUTCOMES; IMPACT; PHARMACODYNAMICS; QUANTIFICATION; INFECTIONS; GUIDELINES; MODELS; SYSTEM; CURVE; AREA;
D O I
10.1111/bcp.14144
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims For vancomycin treatment in obese patients, there is no consensus on the optimal dose that will lead to the pharmacodynamic target (area under the curve 400-700 mg h L-1). This prospective study quantifies vancomycin pharmacokinetics in morbidly obese and nonobese individuals, in order to guide vancomycin dosing in the obese. Methods Morbidly obese individuals (n = 20) undergoing bariatric surgery and nonobese healthy volunteers (n = 8; total body weight [TBW] 60.0-234.6 kg) received a single vancomycin dose (obese: 12.5 mg kg(-1), maximum 2500 mg; nonobese: 1000 mg) with plasma concentrations measured over 48 h (11-13 samples per individual). Modelling, internal validation, external validation using previously published data and simulations (n = 10.000 individuals, TBW 60-230 kg) were performed using NONMEM. Results In a 3-compartment model, peripheral volume of distribution and clearance increased with TBW (both p < 0.001), which was confirmed in the external validation. A dose of 35 mg kg(-1) day(-1) (maximum 5500 mg/day) resulted in a > 90% target attainment (area under the curve > 400 mg h L-1) in individuals up to 200 kg, with corresponding trough concentrations of 5.7-14.6 mg L-1 (twice daily dosing). For continuous infusion, a loading dose of 1500 mg is required for steady state on day 1. Conclusion In this prospective, rich sampling pharmacokinetic study, vancomycin clearance was well predicted using TBW. We recommend that in obese individuals without renal impairment, vancomycin should be dosed as 35 mg kg(-1) day(-1) (maximized at 5500 mg/day). When given over 2 daily doses, trough concentrations of 5.7-14.6 mg L-1 correspond to the target exposure in obese individuals.
引用
收藏
页码:303 / 317
页数:15
相关论文
共 28 条
[21]   Vancomycin: Predictive Performance of a Population Pharmacokinetic Model and Optimal Dose in Neonates and Young Infants [J].
Marsot, Amelie ;
Vialet, Renaud ;
Boulamery, Audrey ;
Bruguerolle, Bernard ;
Simon, Nicolas .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2012, 1 (04) :144-151
[22]   Obesity-associated disorders before and after weight reduction by vertical banded gastroplasty in morbidly vs super obese individuals [J].
Melissas, J ;
Christodoulakis, M ;
Schoretsanitis, G ;
Sanidas, E ;
Ganotakis, E ;
Michaloudis, D ;
Tsiftsis, DD .
OBESITY SURGERY, 2001, 11 (04) :475-481
[23]   Obesity-Associated Disorders Before and After Weight Reduction by Vertical Banded Gastroplasty in Morbidly vs Super Obese Individuals [J].
J Melissas ;
M Christodoulakis ;
G Schoretsanitis ;
E Sanidas ;
E Ganotakis ;
D Michaloudis ;
D D Tsiftsis .
Obesity Surgery, 2001, 11 :475-481
[24]   Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration [J].
Escobar, Leslie ;
Andresen, Max ;
Downey, Patricio ;
Nella Gai, Maria ;
Regueira, Tomas ;
Borquez, Tamara ;
Lipman, Jeffrey ;
Roberts, Jason A. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 44 (02) :163-167
[25]   Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment [J].
Ahmed, Khalid Altigani ;
Ibrahim, Alnada ;
Gonzalez, Daniel ;
Nur, Abubakr O. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 :81-95
[26]   Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery [J].
Wittau, Mathias ;
Paschke, Stephan ;
Kurlbaum, Max ;
Scheele, Jan ;
Ly, Neang S. ;
Hemper, Evelyn ;
Kornmann, Marko ;
Henne-Bruns, Doris ;
Bulitta, Jurgen B. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (01)
[27]   Effects of the Degree of Obesity on Achieving Target Blood Pressure and Metabolic Deterioration in Obese Individuals: A Population-Based Study [J].
Ozturk, Serkan ;
Baltaci, Davut ;
Turker, Yasemin ;
Kutlucan, Ali ;
Yengil, Erhan ;
Deler, Mehmet Harun ;
Gur, Mucahit ;
Ankarali, Handan .
KIDNEY & BLOOD PRESSURE RESEARCH, 2013, 37 (06) :531-539
[28]   Weight Loss After Receiving Anti-Obesity Medications and Gout Among Individuals With Overweight and Obese: A Population-Based Cohort Study [J].
Wei, Jie ;
Wang, Yilun ;
Dalbeth, Nicola ;
Xie, Junqing ;
Wu, Jing ;
Zeng, Chao ;
Lei, Guanghua ;
Zhang, Yuqing .
ARTHRITIS & RHEUMATOLOGY, 2024, :335-345